PF 3864086Alternative Names: PF-03864086; PF-3864086
Latest Information Update: 28 Apr 2009
At a glance
- Originator Pfizer
- Class Analgesics; Antipyretics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 31 Mar 2009 Discontinued - Phase-I for Pain in Belgium (PO)
- 31 Aug 2008 Phase-I clinical trials in Pain in Belgium (PO)